Analysts Upgrade USANA Health Sciences
According to analysts, USANA Health Sciences is doing fine. Happy analysts, happy distributors, happy corporate executives.
USANA Health Sciences (NASDAQ:USNA) has received a consensus broker rating score of 3.00 (Hold) from the one analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating.
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company has operations in 15 markets worldwide, where it distributes and sells its products by way of direct selling. The Company reports operations in two geographic regions: North America and Asia Pacific, which is further divided into three sub-regions; Southeast Asia/Pacific, Greater China, and North Asia.
Brokerages have set a 12-month consensus target price of $100.00 for the company, according to Zacks. Zacks has also assigned USANA Health Sciences an industry rank of 82 out of 265 based on the ratings given to related companies.
A number of research firms have recently commented on USNA. Analysts at Pivotal Research raised their price target on shares of USANA Health Sciences to $125.00 in a research note on Wednesday, February 11th. Separately, analysts at Canaccord Genuity set a $100.00 price target on shares of USANA Health Sciences and gave the company a “hold” rating in a research note on Wednesday, February 11th.
Shares of USANA Health Sciences (NASDAQ:USNA) traded up 0.76% during mid-day trading on Monday, hitting $102.40. The stock had a trading volume of 72,348 shares. USANA Health Sciences has a 52 week low of $63.22 and a 52 week high of $118.84. The stock has a 50-day moving average of $101.6 and a 200-day moving average of $91.35. The company has a market cap of $1.323 billion and a P/E ratio of 18.15.
USANA Health Sciences (NASDAQ:USNA) last released its earnings data on Tuesday, February 10th. The company reported $1.65 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.93 by $0.28. The company had revenue of $227.90 million for the quarter, compared to the consensus estimate of $219.10 million. During the same quarter in the previous year, the company posted $1.27 earnings per share. The company’s revenue for the quarter was up 21.0% on a year-over-year basis. Analysts expect that USANA Health Sciences will post $6.67 EPS for the current fiscal year.
In other USANA Health Sciences news, Director Robert Auciaux sold 5,028 shares of the stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $100.18, for a total value of $503,705.04. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
276 total views, 2 today